Phase 2 N=11 Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
Total Parenteral Nutrition-induced Cholestasis
Primary: Number of Participants With Normalization of Direct Bilirubin — 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Sildenafil for Swimming-Induced Pulmonary Edema (SIPE) Prevention
Edema, Pulmonary · Immersion · Diving
Primary: Number of Participants With Pulmonary Edema — 7; 9 Participants — p=0.317
Phase 2 N=53 Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
Phase 2 N=164 A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.
Ulcerative Colitis
Primary: The Percentage of Subject Achieve Clinical Response at Week 8 — 46.3; 46.3; 43.9; 26.8 percentage of participants
Phase 2 N=343 Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) Participants — 1.610; 1.301 exacerbation per…
Phase 2 N=50 Does Antibiotic Prophylaxis Reduce Wound Complications After Vulvar Excision of Premalignant Lesions
Premalignant Vulvar Lesion · Benign Vulvar Lesion
Primary: Vulvar Wound Complications Compared Between the Two Arms — 6; 10 Participants
Phase 2 N=20 Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).
Cerebral Palsy
Primary: Safety as Assessed by Number of Participants With In-hospital Infusion Toxicity — 0; 0; 0 Participants
Phase 2 N=25 Levetiracetam in Early Psychosis
Psychosis · Schizophrenia · Schizo Affective Disorder
Primary: Change in Cerebral Blood Flow (CBF) — -2.21; -3.83; -1.29 mL / (100g * min)
Phase 2 N=109 JBT-101 in Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Improvement in the Maximum Daily NRS-Pain Score at Day 84 — 6.3; 6.4; 6.0; 6.2 NRS Pain Score — p=0.4190
Phase 2 N=12 Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)
GSD1
Primary: Number of Participants With Adverse Events (AEs) Treatment-Emergent AEs (TEAEs) Serious TEAEs, Discontinuations Due to TEAEs, and Dose-Limiting Toxicities (DLTs) — 1; 1…
Phase 2 N=16 Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Change From Baseline in Time to Stand (TTSTAND) Versus Matched Historical Controls — 0.17; -0.38; -0.11; 0.69 seconds
Phase 2 N=119 A Study of AZD8233 in Participants With Dyslipidemia
Dyslipidaemia
Primary: Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12. — 0.978; 0.206; 0.270; 0.606 Ratio
Phase 2 N=53 A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.
COVID-19
Primary: Number of Participants That Were Hospitalized Due to COVID-19 Symptoms — 0; 0; 0; 0 Participants
Phase 2 N=58 An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Spinal Muscular Atrophy · Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 2
Primary: Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12] — -0.1; 0.0 score on a scale
Phase 2 N=138 Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants